ACE and heart failure: The US Food and Drug Administration (FDA) subsequently approved sacubitril-valsartan on July 7, 2015.12 Since then, guidelines have transitioned toward recommending sacubitril-valsartan over traditional ACE-I/ARBs in patients with heart failure.13